Abstract
Optimizing deep brain stimulation (DBS) programming for movement disorders requires a trial-and-error process evaluating clinical benefit and adverse effects. Recent advances in sensing technology may enable improvements in selecting optimal settings.1 The use of this technology in programming and comparing clinical outcomes to standard of care has not been fully evaluated. For this study, we assessed whether recorded acute local field potential (LFP) biomarkers can be used in the clinic to optimize DBS parameter programming, and we characterized the reliability of LFP biomarkers, specifically within the theta (4-8Hz), beta (13-30Hz), and gamma (35-90Hz) frequency bands.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
